Incyte is expected to report Q3 2026 consensus revenue of $1.16 billion and a GAAP EPS loss of $4.27, with the current stock price of $78.42 trading roughly 10% below the average analyst target of $86.30.
Investors are primarily focused on the net product sales of Jakafi, the company's flagship oncology treatment, which is estimated to reach $738 million for the quarter.
The projected GAAP loss is largely driven by significant one-time research and development charges associated with recent pipeline acquisitions and licensing deals. Beyond Jakafi, analysts are looking for continued commercial momentum from Opzelura as it expands its market share in the dermatology segment.